Market capitalization | €3.14b |
Enterprise Value | €3.19b |
P/E (TTM) P/E ratio | 19.25 |
EV/FCF (TTM) EV/FCF | 52.63 |
EV/Sales (TTM) EV/Sales | 3.84 |
P/S ratio (TTM) P/S ratio | 3.79 |
P/B ratio (TTM) P/B ratio | 5.73 |
Dividend yield | 1.78% |
Last dividend (FY24) | €1.10 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Laboratorios Farmaceuticos forecast:
9 Analysts have issued a Laboratorios Farmaceuticos forecast:
Dec '23 |
+/-
%
|
||
Revenue | 830 830 |
1%
1%
|
|
Gross Profit | 466 466 |
6%
6%
|
|
EBITDA | 244 244 |
12%
12%
|
EBIT (Operating Income) EBIT | 219 219 |
14%
14%
|
Net Profit | 170 170 |
15%
15%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Head office | Spain |
CEO | Juan Encina |
Employees | 2,111 |
Founded | 1946 |
Website | www.rovi.es |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.